odmj
OncoDaily Medical Journal
ODMJ
3067-6444
OncoDaily Medical Journal
US
7267
10.69690/ODMJ-002-0226-7267
Reviews
Unlocking Precision Medicine in Multiple Myeloma: Venetoclax and Novel Targeted Therapies
Hill
Elizabeth
Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
elizabeth.hill@nih.gov
Patel
Roshani
Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
Bolomsky
Arnold
Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
Young
Ryan
Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
26
02
2026
ODMJ-002-0226-7267
Copyright (c) 2026 OncoDaily Medical Journal
2026
OncoDaily Medical Journal
Multiple Myeloma
personalized medicine
Plasma Cell Malignancies
Precision Medicine
Special Series
Targeted Therapy
Venetoclax
production-ready-file-url
[
Martino EA, Mele G, Vigna E, Morabito F, Gentile M. Refining High-Risk Multiple Myeloma: Advancements in Genomic, Clinical, and Prognostic Criteria. Mediterr J Hematol Infect Dis. 2025 Jan 1;17(1):e2025006.
]
[
Kortüm KM, Mai EK, Hanafiah NH, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016 Sep 1;128(9):1226-33.
]
[
Walker BA, Mavrommatis K, Wardell CP, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018 Aug 9;132(6):587-597.
]
[
Brioli A, Melchor L, Cavo M, Morgan GJ. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. Br J Haematol. 2014 May;165(4):441-54.
]
[
Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014 Jan 13;25(1):91-101.
]
[
Tirier SM, Mallm JP, Steiger S, et al. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. Nat Commun. 2021 Nov 29;12(1):6960.
]
[
Cani L, Gupta VA, Kaufman JL. BCL2 inhibition for multiple myeloma and AL amyloidosis. Br J Haematol. 2025 May;206(5):1285-1296.
]
[
Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 2007 Apr 15;109(8):3489-95
]
[
Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood. 1996 Jul 15;88(2):674-81.
]
[
Robillard N, Avet-Loiseau H, Garand R, et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood. 2003 Aug 1;102(3):1070-1.
]
[
El Hussein S, Medeiros LJ, Hu S, Lin P, Wang W. The many faces of plasma cell neoplasms: morphological and immunophenotypical variants of the great imitator. Pathology. 2022 Feb;54(1):32-42.
]
[
Amy Heerema-McKenney, James Waldron, Steven Hughes, et al. Shaughnessy, Clinical, Immunophenotypic, and Genetic Characterization of Small Lymphocyte–Like Plasma Cell Myeloma: A Potential Mimic of Mature B-Cell Lymphoma. American Journal of Clinical Pathology. Volume 133, Issue 2, February 2010, Pages 265–27.
]
[
Paner A, Patel P, Dhakal B. The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma. Blood Rev. 2020 May;41:100643.
]
[
Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci U S A. 1985 Nov;82(21):7439-43.
]
[
Pettersson M, Jernberg-Wiklund H, Larsson LG, Sundström C, Givol I, Tsujimoto Y, Nilsson K. Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood. 1992 Jan 15;79(2):495-502.
]
[
Touzeau C, Ryan J, Guerriero J, et al. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2016 Mar;30(3):761-4.
]
[
Derenne S, Monia B, Dean NM. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood. 2002 Jul 1;100(1):194-9.
]
[
Touzeau, C., Dousset, C., Le Gouill, S. et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014. 28(1): p. 210-212.
]
[
Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017 Nov 30;130(22):2401-2409.
]
[
Matulis SM, Gupta VA, Nooka AK, et al.Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia. 2016 May;30(5):1086-93.
]
[
Punnoose EA, Leverson JD, Peale F, et al. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Mol Cancer Ther. 2016 May;15(5):1132-44.
]
[
Moreau P, Chanan-Khan A, Roberts AW, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017 Nov 30;130(22):2392-2400.
]
[
Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020 Dec;21(12):1630-1642.
]
[
Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study. Lancet Haematol. 2025 Aug;12(8):e574-e587.
]
[
Kaufman JL, Gasparetto C, Schjesvold FH, et al. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. Am J Hematol. 2021 Apr 1;96(4):418-427.
]
[
Mateos MV, et al. Results from the randomized, open-label phase 3 CANOVA study of venetoclax–dexamethasone versus pomalidomide–dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma. Presented at: International Myeloma Society Annual Meeting; 2023.
]
[
Nizar J. Bahlis, Rakesh Popat, Meral Beksac et al. Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis.. J Clin Oncol. 42, 7510-7510(2024).
]
[
Bolarinwa A, Nagaraj M, Zanwar S, et al. Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes. Blood Cancer J. 2025 Apr 4;15(1):57.
]
[
Kaufman JL, Gasparetto C, Kovacsovics TJ, et al. First results from the randomized portion of a phase 2 study of venetoclax plus carfilzomib–dexamethasone vs carfilzomib–dexamethasone in patients with t(11;14) relapsed/refractory multiple myeloma. Presented at: International Myeloma Society Annual Meeting; 2023. Abstract OA-29.
]
[
Abel Costa L, et al. Sonrotoclax plus dexamethasone was tolerable and demonstrated antimyeloma activity in patients with relapsed/refractory multiple myeloma harboring t(11;14). Presented at: International Myeloma Society Annual Meeting; 2024
]
[
Sikander Ailawadhi, Asher A. Chanan-Khan, Jack Khouri, et al. Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light-Chain (AL) Amyloidosis. Blood 2024; 144 (Supplement 1): 1022.
]
[
Wuillème-Toumi S, Robillard N, Gomez P, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia. 2005 Jul;19(7):1248-52.
]
[
Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood. 2002 Mar 15;99(6):1885-93.
]
[
Bolomsky A, Miettinen JJ, Malyutina A, et al. Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. Blood Adv. 2021 Oct 26;5(20):4125-4139.
]
[
Craig RW, Jabs EW, Zhou P, et al. Human and mouse chromosomal mapping of the myeloid cell leukemia-1 gene: MCL1 maps to human chromosome 1q21, a region that is frequently altered in preneoplastic and neoplastic disease. Genomics. 1994 Sep 15;23(2):457-63.
]
[
Schmidt TM, Fonseca R, Usmani SZ. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J. 2021 Apr 29;11(4):83.
]
[
Tron AE, Belmonte MA, Adam A, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018 Dec 17;9(1):5341.
]
[
Al-Odat OS, Elbezanti WO, Gowda K, et al. KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis. Front Pharmacol. 2024 Oct 1;15:1436786.
]
[
Desai P, Lonial S, Cashen A, et al. A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies. Clin Cancer Res. 2024 Nov 1;30(21):4844-4855.
]
[
Rauh U, Wei G, Serrano-Wu M, et al. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nat Cancer. 2024 Oct;5(10):1479-1493.
]
[
Bolomsky A, Vogler M, Köse MC, Heckman CA, Ehx G, Ludwig H, Caers J. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. J Hematol Oncol. 2020 Dec 11;13(1):173.
]
[
Okamoto H, Mizutani S, Tsukamoto T, et al. Robust anti-myeloma effect of TAS0612, an RSK/AKT/S6K inhibitor, with venetoclax regardless of cytogenetic abnormalities. Leukemia. 2025 Jan;39(1):211-221.
]
[
Bolomsky A, Young RM. Pathogenic signaling in multiple myeloma. Semin Oncol. 2022 Feb;49(1):27-40.
]
[
Ocio EM, Fernández-Lázaro D, San-Segundo L, et al. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia. 2015 Mar;29(3):705-14.
]
[
Holkova B, Zingone A, Kmieciak M, et al. A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2016 Mar 1;22(5):1067-75.
]
[
Suzanne Trudel, Nizar J. Bahlis, Christopher P. Venner, et al. Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of Disease Progression to Overcome Treatment Failure: A Trial of the Princess Margaret Phase II Consortium. Blood 2016; 128 (22): 4526.
]
[
Schjesvold F, Paiva B, Ribrag V, et al. Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):e59-e70.
]
[
Costa LJ, et al. Mezigdomide (MEZI) in novel combinations for relapsed or refractory multiple myeloma (RRMM): updated results from the CA057-003 trial. Presented at: International Myeloma Society Annual Meeting; 2025. Abstract.
]
[
Yang Y, Bolomsky A, Oellerich T, et al. Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma. Nat Commun. 2022 Sep 17;13(1):5469.
]
[
Norseth HML, et al. The phase I/II TG01 study – vaccinating against RAS-mutated multiple myeloma. Presented at: European Hematology Association (EHA) Congress; 2025.
]
[
Andrulis M, Lehners N, Capper D, et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013 Aug;3(8):862-9.
]
[
Giesen N, Chatterjee M, Scheid C, et al. A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma. Blood. 2023 Apr 6;141(14):1685-1690.
]
[
Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002 Mar 15;99(6):2185-91.
]
[
Kalff A, Spencer A. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J. 2012 Sep 7;2(9):e89.
]
[
Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998 Nov 1;92(9):3025-34.
]
[
Våtsveen TK, Brenne AT, Dai HY, Waage A, Sundan A, Børset M. FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14). Eur J Haematol. 2009 Nov;83(5):471-6.
]
[
Croucher DC, Devasia AJ, Abelman DD, et al. Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression. Cold Spring Harb Mol Case Stud. 2023 May 9;9(2):a006249.
]
[
Kumar S, et al. Myeloma developing regimens using genomics (MyDRUG) trial: results from the RAS mutation targeting arm. J Clin Oncol. 2022;40(16 Suppl):8055.
]
[
Landgren O, et al. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood. 2024;144(4):359–367.
]
[
Ramberger E, Sapozhnikova V, Ng YLD, et al. The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities. Nat Cancer. 2024 Aug;5(8):1267-1284.
]